The fibroblast growth factor (FGF) 
Recombinant human epidermal growth factor (EGF) was prepared in our laboratory. HRP-anti-M13 mAb was obtained from Amersham Pharmacia Biotech (Uppsala, Sweden). BALB/c-derived 3T3 cells were maintained in
.
Angiogenesis assay using chick embryo chorioallantoic membrane (CAM)
CAM angiogenesis assay was performed as previously described [10] . Briefly, fifteen 5-day old chicken embryos were selected and randomly divided into three groups, which were treated with 20 l of 10 ng/ml bFGF, 20 l of 10 ng/ml bFGF plus 1 M synthesized peptides, or 20 l PBS, respectively. After incubation at 37ЊC for 72 hrs, the blood vessel intensity was recorded. 
Results

Isolation of specific bFGF-binding phage clones
Heptapeptide-library-derived peptide P7 inhibits the mitogenic activity of bFGF
The ability of P7 to block the biological activity of bFGF was first assessed by measuring its inhibitory effect on bFGF-stimulated proliferation of mouse fibroblast cells. As shown in Fig. 3, synthetic P7 peptides mediated strong inhibition of BALB/c 3T3 cell proliferation in a dose-dependent manner. The inhibitory effect was clearly detected in the cultures with as low as 0.0625 M of P7 peptides, and a 50% inhibition (IC50) of cell proliferation was observed at about 1 M.
Heptapeptide-library-derived peptide inhibits angiogenesis in vivo
We next determined the ability of the P7 peptide to inhibit angiogenesis in vivo in a chick embryo CAM neovascularization model [10] . Consistent with the known angiogenic activity of bFGF [1] 
Discussion
Tumour vascularization is closely related to tumour growth and metastasis. Therefore, antiangiogenetic therapy is a promising approach for cancer therapy [11, 12] [2, 3, 16] and both electrostatic and hydropathic complementarities are important in peptide interactions [17] [18] [19] [20] [21] [22] 
